SpringWorks Therapeutics, Inc. (SWTX)
NASDAQ: SWTX · IEX Real-Time Price · USD
45.53
+1.33 (3.01%)
Apr 26, 2024, 4:00 PM EDT - Market closed
SpringWorks Therapeutics Revenue
In the year 2023, SpringWorks Therapeutics had annual revenue of $5.45M. Revenue in the quarter ending December 31, 2023 was $5.45M.
Revenue (ttm)
$5.45M
Revenue Growth
n/a
P/S Ratio
616.76
Revenue / Employee
$23,996
Employees
227
Market Cap
3.36B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.45M | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 35.00M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Oscar Health | 5.86B |
Fortrea Holdings | 3.11B |
Prestige Consumer Healthcare | 1.13B |
Sotera Health Company | 1.05B |
10x Genomics | 618.73M |
iRhythm Technologies | 492.68M |
Axonics | 366.38M |
Axsome Therapeutics | 270.60M |
SWTX News
- 4 days ago - SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 10 days ago - SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024 - GlobeNewsWire
- 7 weeks ago - SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN - GlobeNewsWire
- 2 months ago - SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors - GlobeNewsWire
- 2 months ago - SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 2 months ago - SpringWorks Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - GlobeNewsWire
- 3 months ago - SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire